外照射后接触X线近距离放疗剂量提升作为直肠癌非手术治疗选择:单中心经验结局
本单中心回顾性分析纳入2003至2012年转诊的83例直肠癌患者,这些患者在外照射放化疗/放疗后存在可疑残留病灶(≤3 cm),因不适合手术或拒绝手术而接受接触X线近距离放疗(CXB)剂量提升,多数总剂量90 Gy分3次4周完成。CXB后临床完全缓解(cCR)率为63.8%,中位随访2.5年时83.1%患者无癌生存。
要点
- 外照射后CXB剂量提升后cCR达63.8%,随访结束时83.1%无癌生存
- cCR后复发7例(13.2%),非转移性再生长6例均成功挽救手术
- 可用于不适合手术或拒绝手术的直肠癌患者,作为根治性手术的替代选择
核心结论
- 对EBCRT/EBRT后存在可疑残留病灶(≤3 cm)的选定直肠癌患者,CXB剂量提升可作为根治性手术的替代选择。
- 本系列中持续cCR者局部再生长率低,非转移性再生长者可成功挽救。
- 该方案可为不适合手术的老年或合并症患者及希望避免手术者提供替代治疗选择。
研究设计与样本
- 单中心回顾性研究,检索2003至2012年转诊至该机构的直肠癌患者结局数据。
- 345例连续转诊直肠癌患者中,83例EBCRT/EBRT后存在可疑残留病灶(≤3 cm)并接受CXB剂量提升。
- 患者经初始多学科团队讨论因不适合手术或拒绝手术而转诊,多数接受CXB总剂量90 Gy分3次4周。
- 中位年龄72岁(范围36-87),58例(69.9%)为男性。
- 初始分期cT2 28例、cT3 55例,54.2%淋巴结阳性。
主要发现
- 中位随访2.5年(范围1.2-8.3)。
- EBCRT/EBRT后CXB剂量提升后53例(63.8%)达临床完全缓解(cCR)。
- 53例cCR患者中7例(13.2%)复发,其中6例(11.6%)非转移性再生长者全部(100%)接受挽救手术。
- 研究结束时83例中69例(83.1%)无癌生存。
关键数值与推荐
- CXB剂量提升适用于EBCRT/EBRT后可疑残留病灶≤3 cm的选定患者。
- 多数患者CXB总剂量90 Gy,分3次、4周内完成。
- cCR定义为CXB剂量提升后达到临床完全缓解。
临床怎么用
- 对EBCRT/EBRT后残留≤3 cm、不适合手术或拒绝手术的直肠癌患者,可考虑CXB剂量提升。
- 达到cCR后需随访监测局部再生长,非转移性再生长可行挽救手术。
- 老年或合并症患者可将其作为避免根治性手术的替代方案。
局限性
- 单中心回顾性研究,随访时间有限(中位2.5年)。
- 样本为经选择的转诊患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the outcomes of rectal cancer patients treated with a nonsurgical approach using contact x-ray brachytherapy (CXB) when suspicious residual disease (≤3 cm) was present after external beam chemoradiation therapy/radiation therapy (EBCRT/EBRT). METHODS AND MATERIALS: Outcome data for rectal cancer patients referred to our institution from 2003 to 2012 were retrieved from an institutional database. These patients were referred after initial local multidisciplinary team discussion because they were not suitable for, or had refused, surgery. All selected patients received a CXB boost after EBCRT/EBRT. Most patients received a total of 90 Gy of CXB delivered in 3 fractions over 4 weeks. RESULTS: The median follow-up period was 2.5 years (range 1.2-8.3). Of 345 consecutive patients with rectal cancer referred to us, 83 with suspicious residual disease (≤3 cm) after EBCRT/EBRT were identified for a CXB boost. Their median age was 72 years (range 36-87), and 58 (69.9%) were men. The initial tumor stages were cT2 (n = 28) and cT3 (n = 55), and 54.2% were node positive. A clinical complete response (cCR) was achieved in 53 patients (63.8%) after the CXB boost that followed EBCRT/EBRT. Of these 53 patients, 7 (13.2%) developed a relapse after achieving a cCR, and the 6 patients (11.6%) with nonmetastatic regrowth underwent salvage surgery (100%). At the end of the study period, 69 of 83 patients (83.1%) were cancer free. CONCLUSIONS: Our data suggest that a CXB boost for selected patients with suspicious residual disease (≤3 cm) after EBCRT/EBRT can be offered as an alternative to radical surgery. In our series, patients with a sustained cCR had a low rate of local regrowth, and those with nonmetastatic regrowth could be salvaged successfully. This approach could provide an alternative treatment option for elderly or comorbid patients who are not suitable for surgery and those with rectal cancer who wish to avoid surgery.
引用
- Sun Myint A, Smith FM, Gollins S, et al. Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience. Int J Radiat Oncol Biol Phys. 2017. PMID: 29229327. doi:10.1016/j.ijrobp.2017.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。